Neuroleptic dosing in chronic schizophrenia: A 10-year follow-up

Canadian Journal of Psychiatry

Volumn 42, Issue 1, 1997, Pages 53-57

  Remington, Gary J ^a   Prendergast, Peter ^b   Bezchlibnyk Butler, Kalyna Z ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Whitby Psychiatric Hospital   (Canada)

Author keywords

10 year follow up; chronic schizophrenia; neuroleptic dosing

Indexed keywords

CHLORPROMAZINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUSPIRILENE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE PALMITATE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CHRONICITY; DRUG DOSE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA;

EID: 0030985604     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379704200108     Document Type: Article

References (47)

1. Baldessarini RJ, Cohen B, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:75-91.
2. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50:322-8.
3. Marder SR, Wirshing WC, Van Putten T. Drug treatment of schizophrenia: overview of recent research. Schizophr Res 1991;4:81-90.
4. Reardon GT, Rifkin A, Schwarz A. Myerson A, Siris SG. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989;146:726-9.
5. Johnson DAW, Wright NF. Drug prescribing for schizophrenic out-patients on depot injections: repeat surveys over 18 years. Br J Psychiatry 1990;156:827-34.
6. Vukovic A, Cohen BM, Keck PE Jr, Shedlack KJ. Neuroleptic dosage regimens in psychotic inpatients: a retrospective comparison. J Clin Psychiatry 1990; 51:107-9.
7. Galletly CA. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust N Z J Psychiatry 1992;26:574-6.
8. Seeman M. Clinical applications of drug studies. In: Stancer HC, Garfinkel PE, Rakoff V, editors. Guidelines for the use of psychotropic drugs. New York: Spectrum; 1984. p 169-82.
9. Dorevitch A, Aronzon R, Zilberman L. Medication maintenance of chronic schizophrenic out-patients by a psychiatric clinical pharmacist: 10-year follow-up study. J Clin Pharm Ther 1993;18:183-6.
10. Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical handbook of psychotropic drugs. Toronto: Hans Huber; 1988.
11. Loranger AM. Sex differences in age at onset of schizophrenia. Arch Gen Psychiatry 1984;41:157-61.
12. Angermeyer MC, Kuhn L. Gender differences in age at onset of schizophrenia: an overview. European Archives of Psychiatry and Neurological Sciences 1988; 237:351-64.
13. Hafner H, Riecher A, Maurer K, Laffler W, Munk-Jorgensen P, Stromgren E. How does gender influence age at first hospitalization for schizophrenia? Psychol Med 1989;19:903-18
14. Reicher A, Maurer K, Loffler W, Fatkenheuer B, van der Heiden W, Hafner H. Schizophrenia - a disease of young single males? European Archives of Psychiatry and Neurological Sciences 1989;239:210-2.
15. Folnegovic Z, Folnegovic-Smalc V, Kulcar Z. Characteristics of male and female schizophrenics at first admission. Br J Psychiatry 1990;156:365-8.
16. Gureje O. Gender and schizophrenia: age at onset and sociodemographic attributes. Acta Psychiatr Scand 1991;83:402-5.
17. Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry 1989;46:929-32.
18. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosaging with high-potency and low-potency neuroleptics. Am J Psychiatry 1984;141:748-52.
19. Zito JM, Craig TJ, Wanderling J, Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry 1987;144:778-82.
20. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
21. Jenner P, Marsden CD. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. In: Jankovic J, Tolosa E, editors. Volume 49, Advances in neurology. New York: Raven; 1988. p 417-31.
22. Baker GB, Greenshaw AJ. Effect of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 1989;9:1-44.
23. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;45:754-8.
24. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991;48:739-45.
25. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995; 152:1210-2.
26. Nordstrom AL, Farde L, Weisel FA, Forslund K, Paulie S, Halldin C, and others. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227-35.
27. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
28. 2 receptor occupancy with low-dose haloperidol treatment. Am J Psychiatry 1996; 153:948-50
29. Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophr Bull 1989;15:123-9.
30. McCreadie RG, Flanagan WL, McKnight J, Jorgensen A. High dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry 1979;135:175-9.
31. Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich OE, and others. High dose haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980;67:17-23.
32. Rimon R, Averbuch I, Rozick P, Fijman-Danilovich L, Kara T, Dasberg H, and others. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 1981;73:197-9.
33. Zarifian E, Scatton B, Bianchetti G, and others. High doses of haloperidol in schizophrenia: a clinical, biochemical, and pharmacokinetic study. Arch Gen Psychiatry 1982;39:212-5.
34. Scatton B, Zarifian E, Bianchetti G, Cuche H, Loo H, Morselli PL. High doses of haloperidol in schizophrenia: clinical, biochemical and pharmacokinetic study. L'Encephale 1982;8:1-8.
35. Beckmann H, Laux G. Guidelines for the dosage of antipsycholic drugs. Acta Psychiatr Scand 1990;82(358 Suppl):63S-66S.
36. Remington G, Addington D, Collins EJ, Jones B, Lalonde P, MacCrimmon DJ, and others. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Can J Psychiatry 1996;41:161-6.
37. Cohen BM, Benes FM, Baldessarini RJ. Atypical neuroleptics, dose-response relationships, and treatment-resistant psychosis. Arch Gen Psychiatry 1989; 46:381-3.
38. Kuehnel TG, Liberman RP, Marshall BD Jr, Bowen L. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. In: Liberman RP, editor. Effective psychiatric rehabilitation, new directions for mental health services. San Francisco: Jossey-Bass; 1992;53:67-77.
39. Leblanc G, Cormier H, Gagné M-A, Vaillancourt S. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Can J Psychiatry 1994;39:223-9
40. Smith RC. Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch Gen Psychiatry 1994;51:427-9.
41. Liberman RP, van Putten T, Marshall BD Jr, and others. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry 1994;151:756-9.
42. Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 1983;13:663-70.
43. Salokangas RKR. Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 1983;142:145-51.
44. Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986;73:609-17.
45. Angermeyer MC, Goldstein JM, Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychol Med 1989;19:365-82.
46. Thara R, Rajkumar S. Gender differences in schizophrenia: results of a follow-up study from India. Schizophr Res 1992;7:65-70.
47. Eaton WW, Mortensen PB, Herrman H, Freeman H, Bilker W, Burgess P, and others. Long-term course of hospitalization for schizophrenia, part I: risk for rehospitalization. Schizophr Bull 1992;18:217-27.